Research Article
Variability in Estimated Glomerular Filtration Rate by Area under the Curve Predicts Renal Outcomes in Chronic Kidney Disease
Table 3
Comparison of baseline characteristics between patients with eGFR AUC%_12M ≤ median and eGFR AUC%_12M > median.
| | Characteristics | Initial eGFR AUC%_12M
≤ median (95.7%) | Initial eGFR AUC%_12M
> median (95.7%) | Peak eGFR AUC%_12M
≤ median (88.2%) | Peak eGFR AUC%_12M
> median (88.2%) |
| | Age (year) | 63.3 ± 13.3 | 63.8 ± 13.5 | 63.0 ± 14.0 | 64.1 ± 12.8 | | Male gender (%) | 54.4 | 62.0* | 52.6 | 63.7** | | Diabetes mellitus (%) | 43.2 | 37.3* | 47.0 | 33.4** | | Hypertension (%) | 68.0 | 62.3* | 70.5 | 59.8** | | Cardiovascular disease (%) | 25.5 | 21.2* | 24.2 | 19.2** | | Systolic blood pressure (mmHg) | 140.3 ± 20.5 | 135.7 ± 19.9** | 140.1 ± 21.8 | 135.9 ± 18.4** | | Diastolic blood pressure (mmHg) | 79.5 ± 13.0 | 78.9 ± 11.9 | 79.0 ± 13.4 | 79.4 ± 11.5 | | Body mass index (kg/m2) | 24.6 ± 4.0 | 25.2 ± 3.9* | 24.8 ± 4.0 | 25.0 ± 3.9 | | CKD stage | | | | | | Stage 3 (%) | 30.0 | 52.7** | 27.4 | 55.3** | | Stage 4 (%) | 36.3 | 28.8 | 35.8 | 29.3 | | Stage 5 (%) | 33.7 | 18.5 | 36.8 | 15.4 | | Laboratory parameters | | | | | | Albumin (g/dL) | 3.8 ± 0.5 | 4.0 ± 0.4** | 3.8 ± 0.5 | 4.0 ± 0.4** | | Fasting glucose (mg/dL) | 118.5 ± 45.4 | 114.3 ± 42.0* | 120.1 ± 49.5 | 112.7 ± 30.8** | | Triglyceride (mg/dL) | 125.3 (91–184.8) | 123.5 (91–186) | 127 (93–187) | 123 (89–183) | | Total cholesterol (mg/dL) | 197.9 ± 51.7 | 195.0 ± 51.8 | 196.9 ± 57.5 | 196.1 ± 45.2 | | Hemoglobin (g/dL) | 10.7 ± 2.1 | 11.9 ± 2.3** | 10.6 ± 2.1 | 12.1 ± 2.3** | | Baseline eGFR (mL/min/1.73 m2) | 23.7 ± 13.5 | 30.7 ± 14.1** | 22.8 ± 13.1 | 31.6 ± 14.0** | | Total calcium (mg/dL) | 9.0 ± 0.8 | 9.3 ± 0.6** | 9.0 ± 0.8 | 9.3 ± 0.6** | | Phosphorous (mg/dL) | 4.4 ± 1.0 | 4.0 ± 0.9** | 4.5 ± 1.1 | 3.9 ± 0.8** | | CaXP product (mg2/dL2) | 40.0 ± 9.3 | 36.9 ± 8.1** | 40.0 ± 9.8 | 36.4 ± 7.2** | | Uric acid (mg/dL) | 7.7 ± 1.9 | 7.8 ± 2.1 | 8.0 ± 2.1 | 7.6 ± 1.8** | | Urine protein-to-creatinine ratio (mg/g) | 1300.7 (615.7–2622.4) | 592.6 (249.2–1347)** | 1324 (575.1–2675.3) | 615.3 (249–1340.8)** | | ACEI and/or ARB use (%) | 47.9 | 43.9 | 49.0 | 42.9* | | Days of follow-up (days) | 747 (533–1162) | 993 (630–1395)** | 730 (523–1174) | 1008 (648–1398)** |
|
|
Abbreviations are the same as Table 1.
, compared with patients with eGFR AUC%_12M ≤ median.
|
